Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491376 | 0.87 | MEN1 (0.46) | HTTTP53ALDH1A1KDM4ETSHR | |
| SCHEMBL28980885 | 0.85 | TP53 (0.56) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL29501710 | 0.84 | SMN1; SMN2 (0.48) | ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL38654957 | 0.81 | ALDH1A1 (0.58) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL2652361 | 0.81 | ALDH1A1 (0.58) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL1521052 | 0.81 | TP53 (0.56) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL29029883 | 0.81 | ALDH1A1 (0.42) | HTTALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL23453516 | 0.80 | TP53 (0.59) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL21166646 | 0.80 | TP53 (0.51) | HTTTP53FOLH1MRGPRX4ALDH1A1 | |
| Cyclopropane SCHEMBL542328 | 0.80 | TP53 (0.51) | HTTTP53FOLH1MRGPRX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054244-A1 | CELLULAR DATA LIBRARY AND METHODS OF USING THE SAME | CELLARITY, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-29 | — | — | US | claimed |
| WO-2012027555-A2 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-01 | — | — | WO | claimed |
| US-20250249153-A1 | Improved Synthesis of Taurolidine, Purity Profiles and Polymorphs | CORMEDIX INC. (US) | 2025-08-07 | — | — | US | disclosed |
| WO-2025054244-A1 | CELLULAR DATA LIBRARY AND METHODS OF USING THE SAME | CELLARITY, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4507746-A1 | IMPROVED SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS | Cormedix Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230346905-A1 | PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023201019-A1 | IMPROVED SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS | CORMEDIX INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-1796669-B1 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2009-10-15 | — | — | US | disclosed |
| EP-1796669-A4 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1921917-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| EP-1796669-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007024993-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006039325-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | HTT 3401/4885TP53 1193/4885FOLH1 733/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HTT 3045/4885TP53 4260/4885FOLH1 140/4885 |
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | HTT 2638/4885TP53 3481/4885FOLH1 82/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | HTT 3450/4885TP53 22/4885FOLH1 343/4885 |
| US-20250249153-A1 | Improved Synthesis of Taurolidine, Purity Profiles and Polymorphs | MAPT, UROD, PRNP | HTT 25/4885TP53 1181/4885FOLH1 1084/4885 |
| US-20230346905-A1 | PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN | MEN1, KLK3, NASP | HTT 838/4885TP53 1794/4885FOLH1 80/4885 |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | HTT 3401/4885TP53 1193/4885FOLH1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.